Author:
Weisel Katja,Krishnan Amrita,Schecter Jordan M.,Vogel Martin,Jackson Carolyn C.,Deraedt William,Yeh Tzu-min,Banerjee Arnob,Yalniz Fevzi,Nesheiwat Tonia,Van Sanden Suzy,Diels Joris,Valluri Satish,Usmani Saad Z.,Berdeja Jesus G.,Jagannath Sundar,Martin Tom
Subject
Cancer Research,Oncology,Hematology
Reference38 articles.
1. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management;Rajkumar;Am J Hematol,2020
2. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy;Gandhi;Leukemia,2019
3. Ciltacabtagene autoleucel, a BCMA-directed CAR T-cell therapy in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study;Berdeja;Lancet,2021
4. ClinicalTrials.gov: A study of JNJ-68284528, a chimeric antigen receptor T cell (CAR-T) therapy directed against B-cell maturation antigen (BCMA) in participants with relapsed or refractory multiple myeloma (CARTITUDE-1). Available at: https://clinicaltrials.gov/ct2/show/NCT03548207?term=NCT03548207&draw=2&rank=1. Accessed: May 14, 2021.
5. Legend Biotech: U.S. Food and Drug Administration grants BCMA CAR-T cilta-cel priority review for the treatment for relapsed/refractory multiple myeloma. Available at: https://www.legendbiotech.com/pdf/LEGN_PR_05262021.pdf. Accessed: May 28, 2021.
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献